Third Study Of Novartis Valsartan Drug Found With Questionable Data
This article was originally published in PharmAsia News
A third Japan university has declared a Novartis Pharma study based on clinical trials the school conducted for Diovan (valsartan) blood-pressure drug contained questionable data.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.